CAS: 23708-48-7; Bromo-[5-(Bromomagnesio)Pentyl]Magnesium

上下游产品

CAS号111-24-0 1,5-二溴戊烷 | CAS号7439-95-4 镁标准溶液 | CAS号106795-52-2 1-(2-aminopheny... | CAS号5445-24-9 1-正丙基环己醇 | CAS号111-16-0 庚二酸 | CAS号108-94-1 环己酮 | CAS号462-94-2 1,5-二氨基戊烷 | CAS号4040-74-8 1,1-二甲基硅杂环己烷 | CAS号18148-37-3 1-Chloro-1-meth... | CAS号18339-91-8 1-chloro-1-sila... | CAS号19814-46-1 1,1-diphenylsta... | CAS号2406-34-0 1,1-二氯硅杂环己烷

专利信息

专利号:US-8258362-B2
优先权日:2009-05-04
标 题:Method for the production of α, ω-olefins by using the copper catalyzed coupling reaction of a Grignard reagent with an allylic substrate
发明人：NACHARAJU KRISHNAMURTHY; TAYLOR PAUL D; COONEY MARK J; CRABTREE LARRY A
权利人:NACHARAJU KRISHNAMURTHY; TAYLOR PAUL D; COONEY MARK J; CRABTREE LARRY A; ISP INVESTMENTS INC
摘要:A process for the synthesis of linear α,ω-diolefins from an allylic substrate comprises the steps of a) forming the bis-Grignard reagent XMgCH2(CH2)nCH2MgX from an α,ω-acyclic dihalide with X being a halogen; b) preparing a solution comprising an allylic substrate and a copper catalyst; c) catalyzing a coupling reaction by adding to the solution of step (b) the bis-Grignard reagent of step (a); and d) isolating and purifying the α,ω-olefin coupling reaction product.

专利号:US-8487108-B2
优先权日:2005-11-14
标题 :Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors
发明人：BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T
权利人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T; VITAE PHARMACEUTICALS INC
摘要:The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.